Baird, a prominent financial services firm, recently modified its price target for Nyxoah SA. On March 23, 2026, analyst David Rescott reduced the target to $4.62 from its previous $5.87, while reaffirming a Neutral rating. This change was attributed to updated financial models that consider the company's U.S. market entry, which, despite gaining traction, is still in its nascent stages. Simultaneously, Stifel also adjusted its price target for Nyxoah SA on March 20, 2026, lowering it to $10 from $11, yet retaining a Buy rating. This decision stemmed from various internal model refinements.

These analyst updates follow Nyxoah SA's announcement of its fourth-quarter financial results on March 19, 2026. The company reported a loss per share of EUR 0.59, compared to EUR 0.46 in the prior year. However, revenue significantly increased to EUR 5.64 million from EUR 1.26 million year-over-year. CEO Olivier Taelman highlighted that this quarter marked the first full period of U.S. commercial activity, with revenue exceeding projections. He also noted the encouraging responses from both medical professionals and patients, alongside consistent insurance coverage from major payers and Medicare. Looking ahead, Nyxoah SA anticipates a sequential increase in U.S. net revenue of approximately 25% in both the first and second quarters of 2026, while international revenue is expected to follow established seasonal trends.

The adjustments by Baird and Stifel reflect a nuanced perspective on Nyxoah SA's market potential. While the company's entry into the U.S. market for obstructive sleep apnea treatments shows promise, as evidenced by positive Q4 results and robust feedback, analysts are factoring in the early phase of this expansion. The differing ratings, Neutral from Baird and Buy from Stifel, indicate varied interpretations of the company's growth trajectory and inherent risks, despite the encouraging initial performance in a crucial new market.